COLLEGE OF HEALTH SCIENCES

DEPARTMENT OF NURSING
HOLY NAME UNIVERSITY
CITY OF TAGBILARAN

DRUG STUDY

Name of Patient : John Kanaman______________________ Address : Dampas District, Tagbilaran City, Bohol Impression: Stage 3 burn wounds on his anterior
and posterior torso and entire left arm with Stage 2 burns on his anterior neck
Date Admitted / Seen : November 16, 2021___________ Ward : Surgery Intensive Care Unit Room : 15_________ Status : Single___ Age : 42______ Sex : M___

Date Brand Generic DOSAGE Route & Classification/ Indication Contraindications Nursing Evaluation
Ordered Name Name Frequency Mechanism of Responsibilities
Action
11/16/21 Duramorph, Morphine 2mg IV STAT/ Binds with Relief of All Formulations: BASELINE After giving
Infumorph, Sulfate now, every opioid moderate to Hypersensitivity to ASSESSMENT the course of
Kadian, Onset: 4 hours receptors severe, acute, or morphine. -Assess onset, type, medication:
M-Eslon , Rapid PRN for within CNS, chronic pain; Acute or severe location, -Patient’s
MS Contin, pain inhibiting analgesia during asthma, GI duration of pain. vital signs
MS-IR Peak: 0.3 ascending pain labor, pain due obstruction, known -Obtain vital signs were in
hour pathways. to MI, dyspnea or suspected before giving normal
from pulmonary paralytic ileus, medication. If range.
Duration: Therapeutic edema not severe hepatic/ respirations are -Patient did
3-5 hours Effect: resulting from renal impairment, 12/min or not exhibit
Alters pain chemical severe respiratory less, withhold any adverse
perception, respiratory depression. medication, effects.
emotional irritant. Extended-Release: contact physician. -Patient was
response to Infumorph: Use GI obstruction, -Effect of responding
pain. in devices for acute medication is well to
managing postoperative pain, reduced if full pain treatment as
intractable hypercarbia. recurs evidenced by
chronic pain. Injection: HF due before next dose.
 to lung disease; INTERVENTION improvement
Extended- arrhythmias, -Monitor vital signs and relief of
release: Use only head injury, 5–10 min after IV pain
when repeated seizures, acute administration, 15– verbalizing
doses for alcoholism. Labor 30 min after SQ, pain scale of
extended when premature IM. 3.
periods of time birth expected. -Be alert for
are required Increased decreased
around the intracranial respirations, B/P.
clock. pressure. -Check for adequate
Immediate-Release voiding.
(Tablets, Oral -Monitor daily
Solution): pattern of
Hypercarbia. bowel activity, stool
Extreme consistency; avoid
Caution: COPD, constipation.
cor pulmonale, - Initiate deep
hypoxia, breathing,
hypercapnia, coughing exercises.
preexisting -Assess for clinical
respiratory improvement;
depression, head record onset
injury, increased of pain relief.
ICP, severe -Consult physician
hypotension. if pain
Cautions: Biliary relief is not
tract disease, adequate.
pancreatitis, PATIENT/FAMILY
Addison’s disease, TEACHING
cardiovascular • Discomfort may
disease, occur with
morbid obesity, injection.
adrenal
 insufficiency, • Change positions
elderly, slowly to
hypothyroidism, avoid orthostatic
urethral hypotension.
stricture, prostatic • Avoid tasks that
hyperplasia, require alertness,
debilitated pts, pts motor skills until
with CNS response to drug is
depression, toxic established.
psychosis, seizure • Tolerance,
disorders, dependence may
alcoholism. occur with
prolonged use of
high doses.
• Report ineffective
pain control,
constipation, urinary
retention.
11/16/21 Flamazine , Silver 1% (10 Topical, Acts on cell Prevention, Premature BASELINE After giving
Silvadene, sulfadiazine mg/g) 1% apply wall/cell treatment of neonates, infants ASSESSMENT the course of
SSD, to the membrane in infection in younger than 2 -Determine initial medication:
SSD AF, Onset: affected concentrations second- and mos. Cautions: CBC, serum -Patient did
Thermazene On area 2x a selectively third-degree Renal/hepatic renal/hepatic not exhibit
contact day. toxic to burns. impairment, function test any adverse
bacteria. G6PD deficiency. results. effects.
Peak: Pregnancy INTERVENTION- -Patient was
Unknown Therapeutic Category B. Monitor serum responding
Effect: electrolytes, well to
Duration: Produces urinalysis, renal treatment.
As long bactericidal function, CBC
as applied effect. if burns are
extensive,
therapy prolonged.
 PATIENT/FAMILY
TEACHING
• For external use
only; may discolor
skin.
11/16/21 Tetanus Tetanus 0.5 ml IM STAT/ Vaccines, Prevention Contraindicated in INTERVENTIONs After giving
Toxoid Toxoid now Antisera and against tetanus immunosuppressed •Observe the 12 the course of
Adsorbed, Onset: Immunological. in children and patients and in rights in giving the medication:
Te 2 doses Tetanus toxoid adult. those with medication -Patient’s
Anatoxal vaccine is a immunoglobulin •Monitor vital signs vital signs
Berna Peak: preparation of abnormalities or •Allow the patient to were in
Unknown inactivated severe lie down to prevent normal
toxin produced hypersensitivity or vomiting range.
Duration: by virulent neurologic •Educate the patient -Patient did
> 10 years tetanus bacilli reactions to the to increase fluid not exhibit
(product of toxoid or its intake to prevent any adverse
Clostridium ingredients (such dehydration effects.
tetani). It acts as thimerosal). •Educate patient that -Patient was
as antigen and Also pain and tenderness responding
produces active contraindicated in in the injection site well to
immunity patients with may occur. treatment.
against tetanus. thrombocytopenia • Inform patient of
or any coagulation possible adverse
disorder that reactions.
would • Encourage patient
contraindicate I.M. to report distressing
injection unless the adverse reactions.
potential benefits • Tell patient that
outweigh the risks. immunization
Defer vaccination requires a series of
in patients with injections. Stress the
acute illness; also importance of
defer vaccination keeping scheduled
 during polio appointments for
outbreaks, except subsequent doses.
in emergencies.
Use absorbed
form cautiously in
infants or children
with cerebral
damage,
neurologic
disorders, or
history of febrile
seizures.
11/16/21 Apo- Ranitidine 50mg IVTT Inhibits Short-term Hypersensitivity to BASELINE After giving
Ranitidine , every histamine treatment of ranitidine. OTC: ASSESSMENT the course of
Deprizine Onset: 8hours action at active duodenal Do not use if - Obtain vital signs medication:
FusePaq, Rapid histamine ulcer. Prevention trouble or before giving -Patient’s
Zantac, H2-receptors of of duodenal pain when medication. vital signs
Zantac-75, Peak: gastric parietal ulcer swallowing food, -Obtain history of were in
Zantac-150 Unknown cells. recurrence. vomiting with epigastric/abdominal normal
Maximum Treatment of blood, or bloody or pain. range.
Strength Duration: Therapeutic active benign black stool is INTERVENTION -Patient did
2-2.5 Effect: Inhibits gastric ulcer, present. - Monitor vital not exhibit
hours gastric pathologic GI Do not use 150 mg signs. any adverse
acid secretion. hypersecretory with kidney -Assess mental effects.
Reduces gastric conditions, acute disease (unless status. -Patient was
volume, gastroesophageal medically -Question responding
hydrogen ion reflux disease advised). Cautions: present abdominal well to
concentration. (GERD), Renal/ pain, GI distress. treatment.
including hepatic PATIENT/FAMILY
erosive impairment, TEACHING
esophagitis. elderly pts, history • Do not take
Maintenance of of acute porphyria medicine
healed erosive
esophagitis. within 1 hr of
OTC: Relief of magnesium- or
heartburn, aluminium
acid indigestion, containing antacids.
sour stomach. • Transient burning/
OFF LABEL: pruritus may occur
Treatment of with IV
upper GI administration.
bleeding. • Report headache.
Prevention of
stress-induced
ulcers in ICU.
Anaphylaxis
(adjunct
therapy).
Premedication to
prevent taxane
hypersensitivity.